Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Phase: PHASE2

Enrollment: 212

Sponsor: ANRS, Emerging Infectious Diseases

Summary

Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.

Eligibility Criteria

Inclusion Criteria: * Adult patients with proven HIV-1 infection * Naïve or antiretroviral experienced * CD4 cell count between 200 and 500/mm3 * Plasma HIV RNA load lower than 4 log10 copies/mL * Signed written informed consent Exclusion Criteria: * Immunotherapy * Immunization with the PPV within the past 5 years * Splenectomy * Use of intravenous immunoglobulin within the past 2 months * Chemotherapy or radiation * Any other vaccination within the past 2 months * Severe renal failure * End-stage liver disease * Pregnancy

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT00148824). StuddyBuddy aggregates publicly available trial information.